THE CORPORATE LIBRARY

Related Party Transactions and Outside Related Director Information

Hospira, Inc. (HSP)

3/31/2006 Proxy Information

The spouse of our executive officer, Valentine Yien, is employed by us as a manager. During 2005, he received a fair market rate of compensation which exceeded $60,000.

4/1/2005 Proxy Information

In connection with the April 30, 2004 spin-off, we entered into various agreements with Abbott (our former parent company), including transition services agreements, lease agreements, and manufacturing agreements under which products are purchased and sold. Our agreements with Abbott are more fully described in our Annual Report on Form 10-K for the year ended December 31, 2004. Under these agreements, during 2004:

our net cost for transition services was approximately $13 million;

our cost for the leases and related services was approximately $30 million;

our product sales to Abbott were approximately $180 million; and

our product purchases from Abbott were approximately $84 million.

The spouse of Valentine Yien, our Corporate Vice President and Controller, is employed by us as a manager. During 2004, he received a fair market rate of compensation which exceeded $60,000.

7/15/2004 S-4 Information

Hospira operated as a part of Abbott's Hospital Products and International segments until the spin-off on April 30, 2004. While Hospira was a part of Abbott, Abbott provided Hospira certain services, which included administration of treasury, insurance, payroll, employee compensation and benefits, travel and meeting services, public and investor relations, real estate services, internal audit, telecommunications, computing services, corporate income tax and selected legal services. After the spin-off, Abbott has continued to provide some of those services to Hospira on a temporary basis. We estimate the aggregate value of these services was approximately $5 million and $6 million in the three months ended March 31, 2004 and 2003, respectively, and $7.4 million in 2003, $4.9 million in 2002 and $2.0 million in 2001.

Each of Abbott and Hospira has provided manufacturing services to the other, and some of these arrangements have continued after the spin-off. Under Abbott's and Hospira's internal reporting practices, these services were provided at cost to the purchasing entity. Sales to Abbott amounted to $46 million and $62 million for the three months ended March 31, 2004 and 2003, respectively, and $224 million in 2003, $197 million in 2002 and $148 million in 2001. Product purchases from Abbott were approximately $20 million for each of the three months ended March 31, 2004 and 2003, and $80 million for each of 2003, 2002 and 2001.

4/9/2004 Proxy Information

Some of our directors and all of our executive officers own Abbott common shares and vested Abbott options or are employees or former employees of Abbott. Following the distribution, we expect our directors and executive officers to beneficially own approximately 500,000 Abbott common shares and options to purchase another approximately 1 million Abbott common shares in the aggregate, based on their holdings as of March 31, 2004. Ownership of Abbott common shares and Abbott options by our directors and officers could create, or appear to create, potential conflicts of interest for such directors and officers when faced with decisions that could have disparate implications for Abbott and us.